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Abstract 
Cerebrospinal fluid (CSF) microRNAs (miRNAs) have emerged as potential biomarkers for 
minimally invasive diagnosis of central nervous system malignancies. However, despite significant 
advances in recent years, this field still suffers from poor data reproducibility. This is especially true 
in cases of infants, considered a new subject group. Implementing efficient methods to study 
miRNAs from clinically realistic CSF volumes is necessary for the identification of new biomarkers.  
Methods: We compared six protocols for characterizing miRNAs, using 200-µL CSF from infants 
(aged 0-7). Four of the methods employed extracellular vesicle (EV) enrichment step and the other 
two obtained the miRNAs directly from cleared CSF. The efficiency of each method was assessed 
using real-time PCR and small RNA sequencing. We also determined the distribution of miRNAs 
among different CSF shuttles, using size-exclusion chromatography.  
Results: We identified 281 CSF miRNAs from infants. We demonstrated that the miRNAs could be 
efficiently detected using only 200 µL of biofluid in case of at least two of the six methods. In the 
exosomal fraction, we found 12 miRNAs that might be involved in neurodevelopment.  
Conclusion: The Norgen and Invitrogen protocols appear suitable for the analysis of a large 
number of miRNAs using small CSF samples. 
Key words: CSF miRNAs, CSF exosomes, microRNA profiling, infants, clinical samples  
Introduction 
Cerebrospinal fluid (CSF) is a potential source 
for minimally invasive diagnostic analysis of neuro-
logical disorders, including viral infections [1], 
Alzheimer’s disease [2, 3], traumatic brain injury [4], 
and brain tumors [5-7]. The CSF contains cells, 
extracellular vesicles (EVs), and biomolecules such as 
proteins, nucleic acids, and metabolites. These 









EVs [3, 4] or circulate freely within the fluid [8]. 
Among these components, the microRNAs (miRNAs) 
have been attracting increasing attention in recent 
years [8, 9]. miRNAs are short (∼22 nucleotides) 
non-coding RNAs that modulate gene expression at 
the post-transcriptional level [10]. They regulate more 
than 50% of human genes, including many that are 
related to cancer [11, 12]. Some changes in the levels of 
certain miRNAs have already been associated with 
various pathologies [8]. Teplyuk et al. have found high 
levels of miR-10b and miR-21 in the CSF of patients 
with glioblastoma (GBM). Interestingly, the increased 
levels of these two miRNAs are also associated with 
the metastasis to the brain in patients with primary 
breast and lung cancers [13]. Baraniskin et al. have 
reported that miR-21 and miR-15b are upregulated in 
CSF samples from patients with glioma [14]. 
However, these studies analyzed CSF miRNAs 
without examining their transport in the fluid. The 
distribution of miRNAs among miRNA shuttles in the 
CSF, i.e., proteins, lipoproteins, and EVs (exosomes, 
microvesicles, and apoptotic bodies), can differ 
between normal and pathological conditions [8]. Yagi 
et al. have recently observed that the CSF miRNAs can 
vary between the vesicular and non-vesicular 
fractions. They have shown that the miRNAs 
associated with EVs are different from those found in 
free circulation. miR-1911-5p, miR-1264, and miR-34b, 
among others, are abundant in CSF EVs and not in the 
EV-depleted CSF [15]. EVs are released by all types of 
cells and can enter the bodily fluids [16]. Cancer cells 
also actively release EVs carrying miRNAs, which 
communicate with near and distal cells in the tumor 
microenvironment and affect tumor progression [17, 
18], contributing to the final vesicular composition of 
biofluids. Therefore, miRNAs carried by CSF EVs 
might constitute a good source of biomarkers for 
minimally invasive diagnosis and prognosis of brain 
cancer. Although the CSF is often obtained for 
diagnosis in the clinical practice, the EVs that this 
fluid contains are not routinely examined, neglecting 
most of its biomarker potential. Only one study has 
currently reported a robust CSF EV-associated 
miRNA signature (nine-miRNA catalog) for 
minimally invasive diagnosis of GBM [19]. 
Despite significant advances in recent years, this 
field suffers from poor data reproducibility [20, 21]. 
The main reason for this persistent problem is the 
complexity of CSF miRNA detection procedures, with 
many unresolved technical issues [8]. First, it is crucial 
to preserve the integrity of CSF specimens between 
their collection and laboratory processing and storage. 
The samples should be processed within 2 hours of 
collection, and freeze-thaw cycles should be avoided 
[20]. Second, various existing miRNA isolation 
protocols have different yields. To date, various 
methods and kits have been used to isolate EVs from 
CSF samples [15, 19, 22-28] and to extract miRNAs 
from CSF EVs [15, 19, 22-27, 29] and from cleared CSF 
[9, 13, 14, 30-39]. However, it is difficult to compare 
the data obtained using such a varying array of 
techniques, kits, and samples. Third, different miRNA 
profiling platforms and data normalization 
approaches can result in distinct miRNA catalogs [20, 
36]. In view of the above, the unresolved technical 
issues in the analysis and standardization of protocols 
are still the obstacles to be overcome. Another 
important problem to be considered is the limited 
amount of CSF that can be obtained for the diagnosis. 
In the case of pediatric patients, this problem is even 
more acute since the amount of CSF routinely 
withdrawn for clinical tests is smaller than from the 
adults. For this reason, these patients constitute a 
largely unexplored subject group for which new 
biomarkers are desperately needed [21]. In addition, 
very little is known of the biological variability of the 
CSF microRNAome; it might be affected by the diet, 
health status, age, and development. Establishing a 
standardized, efficient protocol for miRNA detection 
in small CSF samples would facilitate the necessary 
large studies with statistically sufficient numbers of 
subjects. The availability of such methods might also 
help to clarify other issues and identify new 
biomarkers, especially in infants, where they are 
desperately needed [21]. 
Thus, it is necessary to adapt the existing 
protocols to small CSF sample volumes and find the 
most appropriate method for miRNA analysis. Here, 
we performed a comprehensive comparative analysis 
of six existing protocols to establish a simple and 
effective method for detecting miRNAs from a 
minimum CSF volume of clinical specimens. We 
placed particular emphasis on identifying miRNAs 
associated with EVs. We believe that our study 
contributes some valuable data to the search of new 
low-invasive biomarkers for pediatric brain cancers 
and to their implementation in clinical practice. 
Methods 
Experimental design 
In this study, we performed a comprehensive 
comparative analysis of six existing methods to define 
a simple and effective strategy for detecting miRNAs 
from 200-µL samples of CSF. Four of the protocols 
included an initial EVs enrichment step. The other 
two were designed to extract miRNAs directly from 
cleared CSF. First, the efficiency of each method was 
assessed using the real-time PCR (RT-qPCR). Eight 
miRNAs previously detected in the CSF by Yagi et al. 





were selected as reference [15]. We used small RNA 
sequencing (smallRNAseq) data from Yagi et al. as a 
reference throughout our study since they isolated 
miRNAs from a large volume of CSF (7 mL). The eight 
miRNAs had variable concentrations in the exosomal 
fractions of Yagi et al. (Figure S1A) [15]. Our aim was 
to establish the detection limit of each of the methods 
for small CSF volumes (200 µL). Then, the methods 
capable of identifying the majority of the eight 
miRNAs (using RT-qPCR) were examined employing 
the smallRNAseq to find the technique detecting the 
largest number of miRNAs. 
Moreover, the CSF samples were fractionated 
using an in-house size-exclusion chromatography 
(SEC) method. Two fractions representing the 
exosomal and supernatant fractions were sequenced 
to identify enriched miRNAs in the exosomal fraction 
of CSF of infants. Each procedure was carried out in 
triplicate (Figure 1). 
Human CSF samples 
Samples and data from patients included in this 
study were provided by the Basque Biobank (www. 
biobancovasco.org) and were processed following 
standard operation procedures with appropriate 
approval of the Ethical and Scientific Committees 
(code CEIC E17/40). Nineteen non-hemorrhagic 
samples from children (aged 0-7) were acquired. The 
CSF samples were obtained via lumbar puncture, 
centrifuged to remove contaminant cells (500 x g for 
10 minutes), aliquoted, and immediately stored at -80 
°C until processing. To perform the 
main experiment and the analyses of 
reproducibility and RNase protection, 
three independent pools of samples 
were generated. To achieve that, the 
CSF samples were thawed at 4 °C, 
mixed together, centrifuged at 3,000 x g 
for 15 minutes at 4 °C, divided into 200 
µL-aliquots (cleared CSF), and kept on 
ice until processing. 
EVs enrichment procedures 
Four different EV enrichment 
methods were evaluated in triplicate: 
ultracentrifugation (UC), miRCURY 
Exosome Isolation Kit - Cells, Urine and 
CSF (Qiagen #76743) (QIA), Total 
Exosome Isolation Reagent (Invitrogen 
#4484453) (INV), and an in-house SEC. 
UC was carried out in a single step 
(100,000 x g for 75 minutes at 4 °C) 
using a Beckman-Coulter TLA 120.2 
rotor. The QIA kit was used following 
the manufacturer's instructions. The 
INV method was slightly modified; the 
CSF triplicates were not initially 
centrifuged at 10,000 x g, as recomm-
ended, but at 3000 x g like in the rest of 
the protocols. The UC and QIA 
methods required an adjustment of the 
sample volume from 200 µL to 1.0 mL 
using 1X DPBS (Gibco #14190-094). In 
all cases, the EV pellets were resus-
pended in 100 µL of 1X DPBS. Finally, 
the cleared CSF was fractionated using 
the in-house SEC. This was performed 
as follows: The Poly-prep Chromato-
graphy Column (BioRad #731-1550) 
was filled with 2.5 mL of Sepharose 
 
 
Figure 1. Experimental design for comparison of six methods of analyzing miRNAs in bodily fluids. 
Aliquots of 200 µL of CSF were used to test each of the six methods in triplicate (overall, 18 aliquots 
were processed). The pellets obtained in each EV enrichment procedure were resuspended in 100 µL 
of 1X DPBS. Then, total RNA was extracted to perform the downstream analyses (TaqMan RT-qPCR 
and smallRNAseq). Abbreviations: size-exclusion chromatography (SEC), ultracentrifugation (UC), 
miRCURY Exosome Isolation Kit from Qiagen (QIA), Total Exosome Isolation Reagent from 
Invitrogen (INV), mirVana PARIS Kit from Ambion (PAR), and Plasma/Serum RNA Purification Kit 
from Norgen (NOR). 





CL-2B cross-linked resin (Sigma #CL2B300-100ML) 
and left packing overnight at 4 °C. Then, the column 
was washed twice with 2.5 ml of 1X DPBS. Once the 
sample (200 µL of CSF) was applied onto the column, 
4.0 mL of 1X DPBS was added; 10 fractions of 200 µL 
and two final fractions of 1.0 mL were collected. The 
RNA was extracted from the isolated EVs and the SEC 
fractions using the mirVana PARIS Kit (Ambion 
#AM1556) (PAR), following the manufacturer's 
instructions for total RNA isolation. To account for the 
differences in the efficiency of the extraction, the 
samples were spiked with cel-miR-39 (2x10-4 nmoles 
added) (Invitrogen) after mixing the cleared CSF with 
the cell disruption buffer (Figure 1). 
RNA extraction directly from cleared CSF 
Total RNA was extracted from 200 µL of cleared 
CSF using PAR and the Plasma/Serum RNA Purifi-
cation Kit (Norgen #55000) (NOR). The isolated RNA 
was eluted in 100 µL of nuclease-free water (Ambion 
#AM9930). Before each RNA extraction, the samples 
were spiked with cel-miR-39 (2x10-4 nmoles added) 
(Invitrogen) (Figure 1). 
cDNA synthesis 
The cDNA was synthesized from 2 µL of the 
isolated RNA using the TaqMan Advanced miRNA 
cDNA Synthesis Kit (Applied Biosystems #A28007), 
following the manufacturer’s recommendations. To 
account for differences in the retrotranscription 
reaction and for the calculation of relative quantities 
of each miRNA, 2x10-8 nmoles of ath-miR-159a 
(Invitrogen) were added to each reaction. 
Real-Time qPCR assay 
The reaction mix consisted of 5 µL of TaqMan 
Fast Advanced Master Mix (Applied Biosystems 
#4444557), 0.5 µL of TaqMan Advanced miRNA 
Assays (Applied Biosystems #A25576), 1.5 µL of 
nuclease-free water (Ambion #AM9930), and 3 µL of 
cDNA diluted at 1:3 ratio. The following assays were 
performed: ath-miR-159a (478411_mir) and cel-miR- 
39-3p (478293_mir) for detecting the spike-ins, as well 
as hsa-miR-21-5p (477975_mir), hsa-miR-451a (478107 
_mir), hsa-miR-92a-3p (477827_mir), hsa-miR-22-3p 
(477985_mir), hsa-miR-1911-5p (479583_mir), has- 
miR-1264 (478670_mir), hsa-miR-30c-5p (478008_mir), 
and hsa-miR-34b-3p (478049_mir) (Applied Biosys-
tems) to detect the eight miRNAs selected. The 
RT-qPCR reactions were conducted in duplicate on a 
ViiA 7 Real-Time PCR System (Applied Biosystems). 
The data were analyzed using the QuantStudio 
Real-Time PCR System, software version 1.3 (Applied 
Biosystems). 
Western blot analysis of SEC fractions 
First, 200 µL-aliquot of CSF was fractionated 
using SEC as previously described. Then, 150 µL of 
each fraction was concentrated using 99.5% acetone 
(Panreac #161007) and resuspended in 20 µL of 1X 
DPBS. Fifteen µL of the suspension was mixed with 5 
µL of NuPAGE LDS Sample Buffer 4X (Invitrogen 
#NP0007) and heated for 5 minutes at 37 °C, 10 
minutes at 65 °C, and 15 minutes at 95 °C. Each 
preparation was separated in a 4–12% Bis-Tris gel 
(Invitrogen #NP0336BOX) with MOPS SDS Running 
Buffer 20X (Invitrogen #NP0001). Precision Plus 
Protein Dual Color Standard (BioRad #161-0374) was 
used to calculate the molecular weights of the 
proteins. The proteins were transferred to an 
Immobilon-P Transfer membrane (Merck Millipore 
#IPVH00010) using the NuPAGE Transfer Buffer 20X 
(Invitrogen #NP0006-1) and blocked for 1 hour in 5% 
Blotting-Grade Blocker (BioRad #170-6404) and 0.2% 
Tween-20 (Sigma Aldrich #P2287) diluted in 1X 
DPBS. Then, the primary antibodies (1:500) were 
added and incubated overnight, followed by three 
washes with 1X DPBS and the application of 
secondary HRP-conjugated antibodies (1:6000). 
Primary antibodies against exosomal markers, i.e., Mo 
αCD63 clone H5C6 (Developmental Studies 
Hybridoma Bank ID AB_528158) and Mo αCD9 (R&D 
systems #MAB1880), as well as antibodies to detect 
the neuron-specific enolase (NSE) and albumin, i.e., 
Rb αNSE clone EPR3377 (Abcam #Ab79757) and Sh 
αHSA (Abcam #ab8940), were used. HRP-conjugated 
anti-Mo, anti-Rb, and anti-Sh antibodies were 
obtained from Jackson ImmunoResearch. Chemilumi-
nescence detection of bands was performed using 
Pierce ECL Plus Western Blotting Substrate (Thermo 
Scientific #32132). Finally, the antigens were detected 
on high-performance films (GE Healthcare 
#28906844) using the AGFA Curix-60 automatic 
processor (Agfa, Cologne, Germany). 
RNase protection assay 
To detect each miRNA of interest within the EVs, 
we treated the cleared CSF with proteinase K (Sigma 
Aldrich #03115879001) or Triton X-100 (TX-100) 
(Sigma Aldrich #T8787) plus RNase A (Sigma Aldrich 
# 10109142001), as described in Shelke et al. [40, 41]. 
The proteinase K degrades the protein-miRNA 
complexes and, therefore, facilitates the degradation 
of the free-circulating miRNAs by the RNase [41]. 
After this treatment, all the miRNAs that are not 
protected inside the EVs should be degraded. 
However, the TX-100 permeabilizes the membrane of 
the EVs and allows the RNase to degrade the miRNAs 
contained in the vesicles. This assay, in combination 
with the proteinase K experiment, should show which 





miRNAs are associated with vesicles or other CSF 
components. Each procedure was carried out in 
triplicate. Briefly, a CSF pool of 1.8 mL was divided 
into nine aliquots of 200 µL. Three of these were 
incubated with proteinase K (the final concentration, 
0.05 mg/mL) at 37 °C for 10 minutes. The reaction 
was stopped by adding phenylmethylsulfonyl 
fluoride (the final concentration, 5 mM) (Sigma 
Aldrich #10837091001) followed by additional heat 
inactivation (90 °C for 5 minutes). Another three 
aliquots were treated with 0.1% TX-100. Then, the 
samples treated with Proteinase K or TX-100 were 
incubated with RNase A (the final concentration, 0.5 
mg/mL) at 37 °C for 20 minutes. The remaining 
aliquots constituted positive controls; they were not 
treated and kept at 4 °C until the RNA extraction step. 
Afterward, total RNA was extracted using NOR, and 
the levels of the eight miRNAs selected from Yagi et 
al. were determined by RT-qPCR. 
Small RNA sequencing 
The quantity and profiles of obtained RNAs 
were examined using Agilent RNA 6000 Pico Chips 
(Agilent Technologies #5067-1513). Then, sequencing 
libraries were prepared using NEXTflex™ Small 
RNA-Seq Kit v3 (Bioo Scientific Corp. #5132-05) 
following the protocol for NEXTflex™ Small 
RNA-Seq Kit v3 V16.06. Briefly, using 70 of 100 µL of 
each extraction, the total RNA samples were 
incubated for 2 minutes at 70 °C, then 3′ 4N 
adenylated adapter and ligase enzyme were added, 
and ligation was conducted overnight at 20 °C. After 
removal of excess of 3′-adapter, 5′-adapter was added 
with ligase enzyme and the mix was incubated at 
20°C for 1 hour. The ligation product was used for the 
reverse transcription with the M-MuLV Reverse 
Transcriptase in a thermocycler for 30 minutes at 42 
°C and 10 minutes at 90 °C. Next, the enrichment of 
the cDNA was performed using PCR cycling: 2 min at 
95 °C; 22–25 cycles of 20 sec at 95 °C, 30 sec at 60 °C, 
and 15 sec at 72 °C; the final elongation for 2 min at 72 
°C and the reaction was stopped at 4 °C. PCR 
products were resolved on 6% Novex TBE PAGE gels 
(Thermo Fisher Scientific #EC6265BOX), and the band 
between 150 bp and 300 bp was cut out from the gel. 
Small RNAs were extracted from polyacrylamide gel 
using an adapted protocol, in which the DNA from 
gel slices was diffused in ddH2O. Afterward, the 
quantitative and qualitative analyses of the libraries 
were performed on an Agilent 2100 Bioanalyzer using 
Agilent High Sensitivity DNA Kit (Agilent 
Technologies, # 5067-4626) and Qubit dsDNA HS 
DNA Kit (Thermo Fisher Scientific, # Q32854). The 
libraries were single-read sequenced for 51 
nucleotides in a HiSeq2500 System (Illumina). 
Data analyses 
Real-Time qPCR assay 
The relative quantity of each analyzed miRNA 
was calculated using the ath-miR-159a spike-in as the 
reference miRNA and the following formula: ∆Ct=2^ 
- (Ct miRNA - Ct ath-miR-159a). 
Small RNA sequencing 
FASTQs were trimmed for the adapters 
following the recommendations of the NEXTflex™ 
Small RNA-Seq Kit manufacturers. We used Bowtie 
[42] to align the reads against the human genome with 
the corresponding annotations (GRCh38/GENCODE- 
v26), with a mismatch 0, to avoid false positives. 
GENCODE contains a full set of annotations 
including all protein-coding loci with alternatively 
transcribed variants, non-coding loci with transcript 
evidence, and pseudogenes [43]. Quantification of the 
transcriptome was performed using Partek 
expectation maximization, employing Partek Flow 
application, software version 7.0. Only the miRNAs 
with 10 or more reads in the three replicas were 
considered. To estimate the relative miRNA levels 
from smallRNAseq data, the trimmed mean of 
M-values normalization method (TMM) was used 
[44]. To visualize the miRNAs identified by each 
method and their relative abundance, normalized 
data were represented using the pheatmap package 
v1.0.10 (default settings) in R 3.4.1 program 
(2014-04-10, R Foundation for Statistical Computing, 
Vienna, Austria). UpSet plot showing the total size 
and overlaps between the miRNAs sets isolated by 
each method and SEC fractionation was obtained 
using UpSetR [45] (available online in https:// 
gehlenborglab.shinyapps.io/upsetr/). We used the 
smallRNAseq data from Yagi et al. as a reference [15]. 
Data were obtained from the NBDC Human Database 
(dataset ID: JGAS00000000064) (https://humandbs. 
biosciencedbc.jp/en/) and analyzed in the same way 
as our data, to be able to compare the two datasets. 
Correlation analysis 
Correlation coefficients between RT-qPCR and 
smallRNAseq data were calculated using the cor 
function in R 3.4.1 software (2014-04-10, R Foundation 
for Statistical Computing). 
Gene target prediction and pathway enrichment 
analysis 
Predicted target genes for each miRNA were 
obtained using miRWalk 2.0 database [46]. The target 
genes were only selected if they were predicted by at 
least eight of the twelve miRNA-target prediction 
programs hosted in the miRWalk 2.0. Pathway 
enrichment analyses were performed using the over- 





representation analysis module of the Consensus-
PathDB web tool (CPDB) [47]. The default collections 
of Kyoto Encyclopedia of Genes and Genomes 
(KEGG) [48], Reactome [49], and BioCarta (http:// 
cgap.nci.nih.gov/Pathways/BioCarta_Pathways) 
databases were utilized to analyze the predicted 
target gene lists. 
Results and Discussion 
In this study, we compared several existing 
methods used to enrich the EVs and to analyze their 
miRNA cargo. We attempted to establish the most 
suitable technique for detecting CSF miRNAs in 
200-µL samples. This volume was chosen considering 
the realistic amount of CSF that could be obtained 
from each patient to conduct such studies (200–300 
µL). 
Assessing the efficiency of the protocols using 
Real-Time qPCR 
First, the efficiency of the six tested protocols 
was evaluated using RT-qPCR. Eight miRNAs 
previously detected by Yagi et al. that had variable 
concentrations in the exosomal fraction (using 7-mL 
CSF samples) were selected as a reference of the 
biofluid (Figure S1A), including three EV-associated 
miRNAs (miR-1911-5p, miR-1264, and miR-34b-3p) 
and five additional miRNAs identified in both the 
exosomal and non-exosomal fractions (miR-21-5p, 
miR-451a, miR-92a-3p, miR-22-3p, and miR-30c-5p) 
[15]. Among these, miR-21-5p, miR-1911-5p, miR-30c- 
5p, and miR-34b-3p have also been found in the brain 
and cerebellum by Meunier et al. (GEO accession 
number: GSE40499) [50]. Here, we found that, of the 
eight evaluated miRNAs in our pool of samples, the 
four most abundant miRNAs were miR-21-5p, 
miR-451a, miR-92a-3p, and miR-22-3p. By contrast, 
miR-1911-5p, miR-1264, miR-34b-3p, and miR-30c-5p, 
were the least abundant miRNAs in our study (Figure 
2). Yagi et al. have found the miR-1911-5p in the 
exosomal fraction and, to a much lesser extent, in the 
supernatant (Figure S1A). Here, this miRNA was 
detected by RT-qPCR in the transcriptome obtained 
by all the protocols, with and without the enrichment 
step. Similarly, miR-1264, miR-30c-5p, and miR-34b- 
3p, detected by Yagi et al. only in the exosomal 
fraction (Figure S1A), were also found using the NOR 
and INV protocols (Figure 2A). This demonstrated 
that we could harvest miRNAs of different 
abundances in the CSF by analyzing as little as 200 µL 
of fluid. However, these results should be interpreted 
with caution since Yagi et al. have used the CSF from 
healthy adults [15], not from infants. Additional 
studies of healthy infants are needed to corroborate 
our results. 
 
Figure 2. Performance of different protocols measured using RT-qPCR. A, the 
number of TaqMan RT-qPCR replicates (from a total of 12) in which the studied 
miRNAs were detected. Twelve RT-qPCR reactions were performed for each 
method (3 EV isolations and miRNA extractions x 2 cDNA synthesis reactions 
x 2 technical duplicates of each cDNA reaction). B, relative quantification (in 
comparison with ath-miR-159a) of miR-21-5p, miR-451a, miR-92a-3p, and 
miR-22-3p and C, of miR-1911-5p, miR-1264, miR-30c-5p, and miR-34b-3p. 
Abbreviations: ultracentrifugation (UC), miRCURY Exosome Isolation Kit from 
Qiagen (QIA), Total Exosome Isolation Reagent from Invitrogen (INV), mirVana 
PARIS Kit from Ambion (PAR), and Plasma/Serum RNA Purification Kit from 
Norgen (NOR). 
 
Four of the assessed methods, NOR, INV, PAR, 
and QIA, detected the more abundant miRNAs in all 
replicas (12/12), except for miR-22-3p detection by 
QIA (10/12). The methods using total RNA from the 
cleared CSF (PAR and NOR) performed slightly better 
based on our eight reference miRNAs. PAR was the 
most efficient method for the most abundant miRNAs 
tested by RT-qPCR (Figure 2B). However, it did not 
detect the miR-34b-3p, the least abundant miRNA 





evaluated (Figure S1A). In contrast, NOR was the 
most effective method when dealing with low copy 
number, based on the smallRNAseq data of Yagi et al. 
(miR-1911-5p, miR-1264, miR-30c-5p, miR-34b-3p), 
suggesting superior sensitivity (Figure 2C). Among 
the methods employing the EV enrichment step, INV 
obtained the lower Ct values. QIA and UC did not 
perform well with small CSF samples. However, we 
cannot rule out that this difference in performance is 
due to a modification in the INV procedure. INV 
protocol recommends two consecutive centrifugation 
steps before adding the exosome isolation reagent 
(2,000 x g for 30 minutes and 10,000 x g for 30 
minutes). In this study, all the samples were 
centrifuged at 3,000 x g for 15 minutes. Therefore, the 
INV procedure might have obtained both small 
(mainly exosomes) and large EVs, while QIA and UC 
might have achieved more precise exosome 
separation. This is supported by the fact that the 
exosomal miR-1911-5p was the most abundant 
species detected by QIA and UC. In any case, 
the other methods (NOR, INV, and PAR) 
performed better in the detection of the 
reference miRNAs when analyzed by RT-qPCR. 
Interestingly, INV and NOR were the only 
techniques capable of detecting all the miRNAs 
studied here by RT-qPCR, including CSF 
miRNAs associated with the vesicular fraction 
(miR-1911-5p, miR-1264, and miR-34b-3p) 
(Figure 2A) [15]. This suggests that these two 
are the most proficient methods for the analysis 
of low copy number. Overall, these results show 
that each protocol isolates a slightly different 
group of vesicles and miRNAs. 
Characterization of protein and miRNA 
subpopulations in CSF using SEC 
The miRNAs can have different distribu-
tions among the CSF shuttles, such as different 
populations of EVs, RNA-binding proteins and 
lipoproteins. To study the distribution of 
miRNAs among the different CSF structures in 
infants, we fractionated 200 µL of CSF using an 
in-house SEC protocol. First, the performance of 
the method was evaluated by Western blotting 
(Figure 3A). CD63 and CD9 exosomal markers 
were predominantly detected in fractions 3 
(F03) and fractions 3 to 6 (F03-F06), respectively. 
These markers were found in earlier fractions 
than in most of the published reports for SEC 
[51-53]. However, in our SEC method, the 
sample is separated into fewer fractions than 
usual, which might explain this discrepancy. 
The albumin (mostly in F05, F06, and F10) and 
the NSE (in F05 and mainly in F06) were also 
detected. Albumin is the most abundant protein 
in the CSF (245 mg/L) and accounts for 35–80% 
of the total protein content of this biofluid [54]. 
NSE is a valuable biomarker of brain tumors, 
used for assessing neuronal damage and 
formulating the prognosis of brain injury [55]. It 
is upregulated in the biopsies of GBM patients 
[56]. Here, we demonstrated that the level of 
NSE (found at 8 mg/L in the CSF of healthy 
 
 
Figure 3. Size-exclusion chromatography analysis of CSF. A, Western blot analysis of 
CD63, CD9, neuron-specific enolase (NSE), and human serum albumin (HSA) proteins. 
Molecular weights are shown in KDa. B, the number of TaqMan RT-qPCR replicates (from 
a total of 12) in which the studied miRNAs were detected. C, quantification (relative to 
ath-miR-159a) of miR-21-5p, miR-451a, and miR-92a-3p and D, of miR-1911-5p, 
miR-22-3p, and miR-30c-5p. 





individuals [54] could be measured in 200 µL-samples 
of this fluid. Thus, we showed that our in-house SEC 
method could be used for fractionating small volumes 
of CSF.  
We performed a RT-qPCR assay to examine the 
distribution of our eight reference miRNAs among the 
fractions (Figure 3B). We found that miR-21-5p, 
miR-451a, and miR-92a-3p were the most abundant in 
fractions F06, F07, and F09 (Figure 3C). In the case of 
miR-22-3p, relatively large amounts were obtained in 
F05, F07, and F09 (Figure 3D). Overall, these miRNAs 
showed a similar distribution pattern in 12 fractions, 
where the two main miRNA subpopulations were 
observed. The first subpopulation, from F05 to F08, 
co-fractioned with NSE and albumin while the second 
one (from F09 to F12) co-fractioned with the albumin. 
Interestingly, the miR-30c-5p was only detected in the 
fraction F03 (Figure 3D), co- 
fractionating with the exosomal markers. This is in 
agreement with the results of Yagi et al. who have 
found that this miRNA is 3 to 5 times more abundant 
in the vesicular CSF fraction than in the EV-depleted 
CSF [15]. miR-1911-5p, the exosome-associated 
miRNA, was highly expressed in the exosomal 
fraction (F03) and to a lesser extent in F09, also in 
accord with the enrichment in the vesicular fraction 
reported by Yagi et al. [15]. By contrast, miR-1264 and 
miR-34b-3p were not detected using the SEC when 
analyzing 200-µL CSF samples. These miRNAs were 
the least abundant references in our study and were 
detected with fewer than 10 counts by Yagi et al. 
(Figure S1A). Thus, the SEC seems less sensitive than 
the other methods tested here (PAR, INV, and NOR). 
RNase protection assay 
To further analyze the association of miRNAs 
with vesicles and their exact location (inside or on the 
surface of the vesicles), we performed an RNase 
protection assay. The cleared CSF was treated with 
Proteinase K or TX-100, and RNase A. We found that 
most of the miRNAs studied by RT-qPCR (i.e., 
miR-21-5p, miR-451a, miR-92a-3p, and miR-22-3p) 
were degraded after proteinase K and RNase A 
treatment (Figure 4). Therefore, their levels should be 
higher in the supernatant than inside the EVs. 
Although the miR-30c was degraded in the absence of 
TX-100 (Figure 4), this miRNA was associated with 
the vesicular fraction containing CD63 (F03) in our 
SEC experiment (Figures 3A and 3D). The degrada-
tion observed after the treatment with proteinase K 
might be explained by the association of this miRNA 
with the outer surface of the vesicles. The treatment 
with TX-100 permeabilizes the membranes, allowing 
the RNase degradation of miRNAs inside the EVs. It 
resulted in complete degradation of miR-1264 and of 
almost all the miR-1911-5p. By contrast, after 
proteinase K treatment no more than half of these 
miRNAs were degraded, suggesting that a large 
proportion of miR-1264 and miR-1911-5p is protected 
within EVs. This agrees with the results of Yagi et al. 
[15] and our miR-1911-5p data (Figure 4). In 
summary, our results show that miRNAs in CSF are 
both free-floating and associated with EVs, on the 
surface of these vesicles or inside them. 
 
 
Figure 4. RNase protection assay. Relative quantification (with respect to 
ath-miR-159a) of each miRNA evaluated by RT-qPCR. The positive control 
(CTRL) shows the total abundance of each miRNA in this pool of samples. The 
samples were also treated with proteinase K and RNase A (PK+RNase) or 
Triton X-100 and RNase A (TX-100+RNase) to examine the association of 
miRNAs with the vesicles (and their location inside the vesicles or on their 
surface). The three conditions were assessed in triplicate. 
 
CSF miRNA profiling using smallRNAseq 
The methods identifying the majority of the eight 
reference miRNAs, using RT-qPCR (Figure 2), were 
further analyzed. We employed smallRNAseq to 
establish which of these techniques could detect the 
largest number of miRNAs (NOR, INV, or PAR). The 
fractions F03 and the F09 of the SEC were also 
sequenced. We selected the F03 since it contained the 
largest CD63 exosome population as shown by the 
Western blot analysis (Figure 3A), to identify miRNAs 
enriched in the exosomal fraction. F09 was also 
sequenced as a non-vesicular fraction for the 
comparison with F03. As expected, our results 
showed that different protocols yielded a different 
number of reads (Table S1). 
The smallRNAseq data normalization remains a 
hot topic that still needs to be addressed. Several 
approaches have been evaluated. For example, adding 
a synthetic oligonucleotide during RNA extraction 
might serve as an indicator of technical variability. 
Here we spiked with the cel-miR-39 after CSF 
denaturing process; however, the amounts of the 
cel-miR-39 oligonucleotide recovered after 
smallRNAseq were highly variable (in raw reads, 





NOR= 1,421-2,914; INV= 1,450-3,083; PAR= 676-933; 
F03= 285,077-1,502,484; and F09= 249-647). Another 
normalization approach employs non-variable small 
RNAs as endogenous controls. To date, several such 
miRNAs have been proposed to normalize data in 
RT-qPCR experiments involving CSF (let-7c, miR-21, 
miR-24, miR-99b, miR-125, miR-328, miR-1274, 
RNU6B, and RNU44) [8]. Sorensen et al. found the 
best normalizer as the average Ct value of the 9 
miRNAs detected in all samples [31]. However, none 
of the small RNAs has shown stable levels in all 
pathological conditions and CSF components [19]. 
Sorensen et al. used the trimmed mean of M-values 
normalization (TMM) for NGS data normalization [31, 
44]. Yagi et al. have presented their data in counts per 
million after applying a normalization factor based on 
the relative log expression method [15]. In other 
words, there is no standard normalization strategy 
[20]. Establishing a common approach is crucial if we 
are to make unbiased comparisons between studies 
[8].  
Overall, 281 different miRNAs were identified 
(the sum of all unique miRNAs detected in our study), 
and the FASTQ data were made available in GEO 
(accession number GSE122068). Our comparisons 
showed that NOR and INV methods identified the 
largest number of miRNAs (238 and 234, respect-
tively). Of these, 198 were detected by both methods. 
However, NOR identified a subpopulation of 
miRNAs that were not detectable by INV and vice 
versa (35 and 30 miRNAs, respectively) (Figure 5 and 
Figure S2). Interestingly, one of the EV-enriched 
methods, the INV, revealed a 30-miRNAs 
subpopulation not detectable by the other methods 
(Table S2). PAR identified 170 miRNAs, and only 7 of 
them were exclusively detected by this method. In the 
SEC fractions F03 and F09, 60 and 67 miRNAs were 
detected, respectively (Figure 5). Of these, 48 miRNAs 
were common for the two fractions (Figure 5 and 
Table S3). However, we identified a subset of 12 
miRNAs in the vesicular fraction (F03) not found in 
the supernatant (F09) that could be considered 
vesicle-associated miRNAs (Figure 6). 
It is remarkable that all the miRNAs detected in 
the SEC fractions were also found using the NOR and 
INV protocols (Figure S2). We can conclude that both 
the NOR and INV protocols are suitable for analyzing 
large catalogs of vesicular and non-vesicular miRNAs 
in small CSF samples from infants. 
We compared our smallRNAseq data with the 
data of Yagi et al. (Figure S1B). We identified 86 out of 
the 92 miRNAs found by these authors after applying 
our cut-off criterion (10 or more counts) (Figures S1B 
and S1C). For the detection of exosomal miRNAs, 
NOR and INV were the methods that best harvested 
the Yagi’s exosome-associated miRNAs from only 200 
µL of fluid (78/85 and 77/85, respectively). However, 
we failed to detect several miRNAs found by Yagi 
(NOR = 7/85 and INV = 8/85) (Figure S1C). These 
miRNAs were detected at low levels in the study of 
Yagi et al. even though they used 7-mL samples of the 
fluid (all of them obtained less than 65 raw reads). 
Their low abundance is the most likely reason for 
missing these molecules in small-volume samples. By 
contrast, we identified a large number of miRNAs 
that Yagi et al. have not detected, using NOR and INV 
(160 and 157, respectively). This suggests that these 
protocols perform better than the UC method used by 
Yagi. However, our results should be interpreted with 
caution since those authors have analyzed samples 
from healthy adults (aged 37-79) rather than from 
infants. Therefore, the discrepancies between the two 
sets of data might be due to biological variability 
among subjects, apart from the differences between 
the protocols. Thus, further studies using samples 
from healthy infants are needed to confirm our 
results. 
Reproducibility assessment 
To test the reproducibility of the RT-qPCR 
assays, the coefficient of variation (CV, %) was 
calculated for each of the eight reference miRNA and 
method (standard deviation/mean of quantification, 
relative to ath-miR-159a)*100. Only the miRNAs 
detected in all the replicas were considered. NOR had 
the lowest coefficient of variation (25.6%), followed by 
INV and PAR (33.0 and 40.5%, respectively). The 
results for spiked-in cel-miR-39 showed the variability 
of 15.3% when using NOR. By contrast, in this case, 
INV showed the highest variability (69.5%) and PAR 
method was not considered since it only detected this 
miRNA in 6 out of 10 replicas (Table 1). 
 
 
Figure 5. UpSet plot showing the total set size and overlaps between the 281 
unique miRNAs and those isolated by each method (PAR, INV, and NOR) or 
found in the F03 and F09 fractions of the SEC. The number of common miRNAs 
detected by each method is indicated on the y-axis. The shaded circles 
connected by solid lines in the lower panel show the intersecting miRNA 
datasets. 






Figure 6. A, a pie chart showing the 12 miRNAs detected in the exosomal fraction but not in the F09 fraction of the size-exclusion chromatography. B, the most 
representative pathways predicted by ConsensusPathDB considering the 3,638 target genes of these 12 miRNAs. 
 
Table 1. Coefficients of variation (CV, %) for each miRNA and 
method evaluated.  
miRNA PAR  INV  NOR 
N CV (%)  N CV (%)  N CV (%) 
cel-miR-39    10 69.5  10 15.3 
hsa-miR-21-5p 10 39.1  10 22.2  10 30.5 
hsa-miR-451a 10 35.4  10 24.0  10 24.2 
hsa-miR-92a-3p 10 36.6  10 27.4  10 30.8 
hsa-miR-22-3p 10 52.7  10 21.9  10 13.9 
hsa-miR-1911-5p         
hsa-miR-1264         
hsa-miR-30c-5p 10 38.7     10 39.1 
hsa-miR-34b-3p         
Mean CV (%) 40.5 ± 7.0  33.0 ± 20.5  25.6 ± 9.8 
NOR had the lowest coefficient of variation, followed by the INV and PAR 
methods. Only the cases in which the miRNAs were detected in all 10 replicates 
were considered. Abbreviations: number of replicates analyzed (N), mirVana 
PARIS Kit from Ambion (PAR), Total Exosome Isolation Reagent from Invitrogen 
(INV), and Plasma/Serum RNA Purification Kit from Norgen (NOR). 
 
The differences between RT-qPCR and 
smallRNAseq data were also examined. Although 
most of the miRNAs found using RT-qPCR were also 
identified by smallRNAseq, miR-34b-3p was detected 
by INV and NOR only in 2/3 of the replicates. 
Similarly, in F03, miR-1264 was found in only 2/3 of 
the replicates. After applying our detection criterion 
(10 or more counts), miR-1264 and miR-34b-3p were 
treated as non-detected. However, these two miRNAs 
were identified by RT-qPCR when the samples were 
processed using PAR, INV, and NOR protocols 
(Figure 2). This confirmed the opinion that RT-qPCR 
is suitable for low copy number RNA samples and 
samples with undefined normalizer molecules, such 
as the CSF [8]. The correlation coefficients for the six 
miRNAs were 0.81 for PAR, 0.84 for NOR, and 0.92 
for INV, showing good agreement between both 
strategies (Figure 7). Our results are in accord with the 
report of Yagi et al. who also evaluated the consistency 
of these techniques [15]. 
Gene target prediction and pathway 
enrichment analysis 
We used our smallRNAseq data to predict the 
target genes and the related pathways in which they 
might be involved. We identified 9,952 target genes 
for the 281 miRNAs detected in our CSF study by 
smallRNAseq, which were then used to perform 
pathway enrichment analyses employing the default 
collections of KEGG, Reactome, and BioCarta. The 





three most significant pathways were axon guidance 
(p = 2.83e-23), membrane trafficking (p = 5.05e-22), 
and vesicle-mediated transport (p = 7.36e-21). A 
complete list of predicted pathways is shown in Table 
S4. The membrane trafficking and vesicle-mediated 
transport pathways are involved in the release and 
internalization of various components from the 
extracellular space by the EVs. The axon guidance 
pathway was also overrepresented. The axon 
guidance process is an important event in 
neurodevelopment; it is related to neuron maturation 
and the formation of neuronal connections in the first 
years of life [57]. We repeated this analysis using the 
3,638 target genes of the 12 miRNAs detected in the 
exosomal fraction (F03) but not in the F09 (Figure 6). 
Overall, the identified pathways are consistent with 
the source of samples for our study, in which the 
EV-associated miRNAs were analyzed in a cohort of 
infants from 0 to 7 years old. Our results indicate that 
the analysis of miRNAs in CSF fluid might become a 
useful, minimally invasive tool to examine the 
physiological and pathological processes affecting 
brain performance. 
NOR as a potential tool in CSF diagnosis 
Overall, the NOR and INV methods obtained the 
best results in the two analyses performed (RT-qPCR 
and smallRNAseq). The main difference between 
NOR and INV is the miRNA isolation procedure. Two 
important aims of standardization should be the 
simplicity and reproducibility of the protocol. Among 
the methods tested here, NOR used the easiest and 
shortest protocol (as can be seen in Figure S3). It also 
was the most reproducible method when tested with 
RT-qPCR, and showed a good correlation between 
RT-qPCR and smallRNAseq techniques. Moreover, 
this protocol detected more miRNAs than the INV. 
Therefore, this might be the best method to analyze 
small-volume samples of CSF. 
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Figure 7. Comparison between the quantification (relative to ath-miR-159a) 
obtained using RT-qPCR and the normalized smallRNAseq counts (represented 
on a logarithmic scale) for six reference miRNAs considered and method 
compared. A, mirVana PARIS Kit from Ambion. B, Total Exosome Isolation 
Reagent from Invitrogen. C, Plasma/Serum RNA Purification Kit from Norgen. 
The miR-1264 and miR-34b-3p were not considered. The correlation 
coefficients between RT-qPCR and smallRNAseq data for each method are also 
shown (upper panel for each method). 
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